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Abstract
Background: Proteolytic degradation of amyloid β (Aβ) peptides has been intensely studied due to the central role of
Aβ in Alzheimer’s disease (AD) pathogenesis. While several enzymes have been shown to degrade Aβ peptides, the
main pathway of Aβ degradation in vivo is unknown. Cerebrospinal fluid (CSF) Aβ42 is reduced in AD, reflecting
aggregation and deposition in the brain, but low CSF Aβ42 is, for unknown reasons, also found in some inflammatory
brain disorders such as bacterial meningitis.
Method: Using 18O-labeling mass spectrometry and immune-affinity purification, we examined endogenous proteolytic
processing of Aβ in human CSF.
Results: The Aβ peptide profile was stable in CSF samples from healthy controls but in CSF samples from
patients with bacterial meningitis, showing increased leukocyte cell count, 18O-labeling mass spectrometry
identified proteolytic activities degrading Aβ into several short fragments, including abundant Aβ1–19 and
1–20. After antibiotic treatment, no degradation of Aβ was detected. In vitro experiments located the source
of the proteolytic activity to blood components, including leukocytes and erythrocytes, with insulin-degrading
enzyme as the likely protease. A recombinant version of the mid-domain anti-Aβ antibody solanezumab was
found to inhibit insulin-degrading enzyme-mediated Aβ degradation.
Conclusion: 18O labeling-mass spectrometry can be used to detect endogenous proteolytic activity in human
CSF. Using this technique, we found an enzymatic activity that was identified as insulin-degrading enzyme
that cleaves Aβ in the mid-domain of the peptide, and could be inhibited by a recombinant version of the
mid-domain anti-Aβ antibody solanezumab.
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Background
The significance of proteolytic degradation products
of proteins and peptides in the central nervous sys-
tem (CNS) relate not only to their potential use as
biomarkers of disease activity, but also to the under-
standing of disease mechanisms. Amyloid β (Aβ) pep-
tides are intensely studied due to their central role in
Alzheimer’s disease (AD) [18, 19, 26]. Aβ is produced
from neurons by sequential cleavage of amyloid pre-
cursor protein (APP) by the β- and γ-secretases [5],
and released into the interstitial fluid of the brain,
which communicates freely with the cerebrospinal
fluid (CSF). Aβ is cleared from the brain by several
pathways including both extra- and intra- cellular
proteolytic degradation, resulting in the production of
a large number of different peptides found in brain
tissue and CSF [37]. Aβ is also cleared across the
blood-brain barrier into the blood, and by CSF
absorption into the circulatory or lymphatic system
(for review see [49]). While Aβ is effectively degraded
in the blood, it is not clear to which extent it is
degraded in the interstitial fluid or CSF [24].
AD patients have reduced CSF levels of the 42 amino
acid long peptide Aβ42 [6, 36], but low CSF Aβ concen-
tration has also been found in infectious or inflamma-
tory CNS disorders, for example in patients suffering
from bacterial meningitis, neuroborreliosis, multiple
sclerosis and HIV with CNS engagement [17, 27, 28, 33,
46, 50]. In bacterial meningitis, low CSF Aβ42 normal-
izes after proper antibiotic treatment, and it has been
hypothesized that the decrease in CSF Aβ42 during the
acute infection may be caused by impaired clearance of
Aβ from the brain, and not related to the inflammation
in itself [46]. Another explanation may be increased ac-
tivities of APP and Aβ metabolizing enzymes with
inflammation.
In the current work, we explore for the first time the
use of proteolytic 18O labeling and mass spectrometry
(MS) to detect endogenous proteolytic activity in human
CSF. CSF was collected from patients with bacterial
meningitis before and after successful treatment with an-
tibiotics. The samples were incubated with 18O-enriched
water and subjected to immunoaffinity purification of
Aβ followed by MS to measure the degree of incorpor-
ation of 18O into proteolytically produced Aβ peptides,
enabling determination of the relative amount of pep-
tides formed by endogenous proteolytic activity in the
CSF. Using this approach, we identified products of a
specific Aβ-degrading activity in CSF from meningitis
patients in the acute phase. This activity, likely derived
from blood cell components in the CSF, was identified
to arise from insulin-degrading enzyme (IDE), possibly
representing a major degradation pathway of Aβ. We
also show that this proteolytic activity can be blocked by
a recombinant version of the mid-domain anti-Aβ anti-
body solanezumab that has an epitope covering the
discovered cleavage site on Aβ.
Methods
Study subjects
CSF was provided from the Clinical Neurochemistry
Laboratory, Mölndal, Sweden. The samples were surplus
from the clinical routine, used after de-identification.
The samples were taken from patients with neurochem-
ical signs of meningitis including increased CSF cell
counts and CSF/serum albumin ratio (see Table 1 for
demographics). Blood samples were obtained from
healthy volunteers. Erythrocyte concentrate (225–340 ml
prepared from 400 to 450 ml whole blood) was provided
by the Blood Center at the Sahlgrenska University Hos-
pital. The study was approved by the local Institutional
Review Boards and was performed in accordance with
the ethical standards laid down in the 1964 Declaration
of Helsinki.
Proteolytic 18O-labeling in CSF
The CSF samples (1 ml) were pH-stabilized by addition
of 1 M HEPES buffer, pH 7.4 to a final concentration of
100 mM. H2
18O (Sigma) were added to the samples at
a 1:1 ratio (v/v), and the samples were incubated for
24 h at room temperature. The samples were stored
at −80 °C pending analysis.
Aβ immunoaffinity purification
Aβ peptides were immunoprecipitated using Aβ-specific
antibodies coupled to magnetic beads as described previ-
ously [38]. Briefly, 4 μg of the anti-Aβ antibodies 6E10
and 4G8 (Signet Laboratories, Dedham, MA, USA) were
Table 1 Clinical characteristics in the study groups. Cell count is
n/μl CSF (reference range < 4 /μl). Albumin is mg/l (reference
range < 400 mg/l)
Patient no. Disease phase CSF cell count CSF Albumin
Polynuclear Mononuclear
1 Acute phase 31 43 560
After treatment 0 2 259
2 Acute phase 445 80 3132
After treatment 0 15 215
3 Acute phase 364 80 2546
After treatment 2 37 143
4 Acute phase 310 12 665
After treatment 46 4 211
5 Acute phase 9000 900 1650
After treatment missing missing 1710
6 Acute phase 3400 744 missing
After treatment 17 60 361
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separately added to 50 μL each of magnetic Dynabeads
M-280 Sheep Anti-Mouse IgG (Invitrogen, Carlsbad,
CA, USA). The 6E10 and 4G8 antibody-coated beads
were mixed and added to the CSF samples to which
0.025% Tween20 in phosphate-buffered saline (pH 7.4)
had been added. After washing, the Aβ peptides were
eluted using 100 μL 0.5% formic acid.
Mass spectrometry
Mass spectrometry was performed using a matrix-
assisted-laser-desorption/ionizationtime-of-flight/time-
of-flight (MALDI TOF/TOF) instrument (UltraFleX-
treme, Bruker Daltonics, Bremen, Germany). Samples
were prepared as described previously [38].
Test of Aβ degrading activity in CSF containing trace
amounts of blood
The isotope labeled Aβ peptide Aβ1-40 Arg13C15N
(Anaspec, Inc., San Jose, USA) was dissolved in
dimethylsulfoxide (DMSO, Aldrich) to a concentration
of 1 mg/mL. The stock solution was aliquoted and im-
mediately stored at −20 °C. Before use the labeled pep-
tide was diluted and mixed to a final concentration of
0.8 μM. A 10-μL aliquot of the peptide solution was
added to 930 μL CSF to which blood was added at dif-
ferent final concentrations (0, 0.05, 0.5, 5% (v/v))
followed by incubation in room temperature overnight
at room temperature. IP-MS was conducted as described
above.
In vitro test of Aβ1-40 degradation by IDE
An aliquot (10 μL) of a 0.8 μM solution of the isotopic
labeled Aβ1-40 (Arg13C15N) was added to 980 μL CSF
and incubated 5 min in room temperature. Recombinant
human IDE (R&D systems) was diluted in 50 mM am-
monium bicabonate to 23.6 ng/mL and 5.9 ng/mL.
10 μL of each solution was added to two separate pre-
incubated CSF samples and left over night in room
temperature. Immunoprecipitation and mass spectrom-
etry were conducted as described above.
Inhibition of IDE activity by insulin
The inhibition of IDE activity was addressed by adding
isotopic labeled Aβ1-40 (Arg13C15N, end concentration
10 ng/mL) to CSF followed by addition of recombinant
human IDE (0.1, 1 or 10 μM, Sigma) and 0.5% human
blood. The samples were incubated overnight at room
temperature. Immunoprecipitation and mass spectrom-
etry were conducted as described above.
Identification of Aβ degrading activity in leukocytes,
thrombocytes, and erythrocytes
Leukocytes and thrombocytes were isolated from 10 mL
blood as described previously [13, 35]. The cells were
resuspended in 500 μL ultra-pure water, lysed by four
freeze/thaw cycles and finally centrifuged 10 min (+4 °C,
31,000 x g). Erythrocytes were prepared using a Reveos
automated blood component extractor.
To 100 μL ammonium bicarbonate, spiked with 5
pmol/μL isotopic labeled Aβ1-40, 5 μL leukocytes,
thrombocytes, or erythrocytes were added, followed by
incubation overnight at room temperature. Immunopre-
cipitation and mass spectrometry were conducted as
described above.
The effect of antibodies on Aβ degradation
To 1 ml PBS containing isotopic labeled Aβ1-40
(0.016 μM) 4 μg of each of the recombinant antibodies
solanezumab, bapineuzumab and crenezumab were
added [8, 53], followed by incubation for 1 h at room
temperature. The antibodies were expressed and purified
as previously described [53]. Each sample was spiked
with serum (5%, end concentration) followed by incuba-
tion overnight at room temperature. The samples were
placed in a 100 °C heating block for five minutes to dis-
rupt potential antibody/Aβ complexes, and subsequently
centrifuged for 10 min at 4 °C (31.000 x g). The superna-
tants were transferred to new tubes and Aβ peptides
were immunoprecipitated and analyzed by mass spec-
trometry as described above.
Isotope distribution calculations
Theoretical peptide isotope distributions with and with-
out incorporation of one 18O atom at 50% abundance
were calculated using the software Isotope Distribution
Calculator v 0.3 [21]. The fractional abundance of Aβ
peptides, produced by proteolysis during the incubation
period, was calculated by linear regression analysis
according to Mirgorodskaya et al. [31], based on the
observed isotope distributions of the detected peptides.
Results
Proteolytic 18O labeling detects aberrant Aβ processing in
the CSF during acute bacterial meningitis
Initial experiments had shown that a patient in the acute
phase of bacterial meningitis displayed an abnormal Aβ
peptide pattern (Additional file 1: Figure S1). To test for
Aβ/APP proteolytic processing in the CSF, H2
18O was
added to CSF samples at a volume ratio of 1:1, followed
by incubation at room temperature for 24 h. The sam-
ples were then subjected to Aβ immunoprecipitation,
and analyzed by MALDI-TOF MS [39]. In control sam-
ples (Fig. 1a), a normal Aβ peptide pattern was observed,
as previously reported [39], and the isotope distributions
of the Aβ peptide signals did not differ from samples not
incubated with H2
18O (data not shown), indicating that
there is no proteolytic activity affecting the Aβ peptides
in normal CSF. In contrast, in CSF samples from
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patients (Table 1) in the acute phase of bacterial menin-
gitis (Fig. 1b), a strong signal at m/z 2461.17 (monoiso-
topic mass) was present, corresponding to Aβ1-20 as
verified by MS/MS (data not shown). In three of the
patients the appearance of this signal was accompanied
by an apparent decrease in Aβ1-40 (m/z 4328.16). In
CSF samples from bacterial meningitis patients taken
after antibiotic treatment (Fig. 1c), the normal Aβ pep-
tide pattern was restored. In addition, two unidentified
compounds at m/z 3369.45 and 3440.50 were detected
in three of the patients in the acute phase. Peaks at these
m/z values were also detected in blood-containing sam-
ples (see below), indicating blood as their likely source
of origin.
Incubation of the samples in H2
18O results in the
incorporation of 18O at the C-terminal carboxy group of
peptides formed by proteolysis, resulting in a molecular
mass shift of +2 or + 4 Da. The mix of labeled/unlabeled
A
B
C
D E
Fig. 1 MALDI-TOF MS CSF Aβ peptide patterns of a a non-symptomatic control, b Patient 1 in the acute phase of BM and c after antibiotic
treatment. The recorded isotope patterns of d Aβ 1–20 and e Aβ 1–40 in acute BM are shown in blue bars, and the expected isotope
patterns of the peptides without 18O incorporation and with one oxygen atom exchanged for 18O at 50% abundance is indicated by red
and green bars, respectively
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peptides resulting from partial labeling and unlabeled
peptide formed prior to addition of H2
18O manifests in
the mass spectra as a broadening of the natural isotopic
peak distribution. In Fig. 1d and e, the red bars represent
the theoretical isotope distributions of Aβ1-20 and Aβ1-
40 without incorporation of 18O. The green bars indicate
the theoretical distributions expected from incorporation
of one 18O at 50% abundance, representing full incorp-
oration under the give experimental conditions. By
comparing the theoretical isotope distributions with the
recorded isotopic peak distributions, the fractional abun-
dance of proteolytically produced Aβ1-20 and 1-40 was
calculated by linear regression analysis [31] for all pa-
tients before and after treatment (Table 2). In five out of
six patients the fractional abundance was close to one,
i.e., the recorded isotope distribution of Aβ1-20 corre-
sponded to the calculated isotope distribution of the
peptide with exchange of one 16O oxygen atom for 18O
at 50% abundance (Fig. 1d), implying that this peptide
was mostly formed by proteolysis in CSF during the
experiment. In contrast, the fractional abundance of
18O-Aβ1-40 was close to zero, i.e., its isotope distribu-
tion indicates no incorporation of 18O (Fig. 1e). Thus
the Aβ1-40 peptide was not formed by proteolytic cleav-
age in the CSF.
Blood contamination in the CSF produces acute bacterial
meningitis -like Aβ degradation
Considering the possibility that the proteoloytic activity
found in bacterial meningitis CSF represented an enzym-
atic activity derived from blood we next incubated CSF
from a healthy individual, spiked with stable isotope
Table 2 Fraction Aβ 1–20 formed during incubation of CSF at
room temperature for 24 h, calculated based on the altered
peptide isotope distribution due to the incorporation of H2
18O
Aβ1-20 Aβ1-40
Patient # Before
treatment
After
treatment
Before
treatment
After
treatment
1 1.14 ND −0.03 0.05
2 1.10 ND 0.12 −0.10
3 1.10 ND 0.16 0.04
4 0.59 0.15 0.18 −0.16
5 1.02 0.27 ND 0.04
6 1.06 0.22 −0.08 0.21
A
B
C
D
Fig. 2 MALDI-TOF mass spectra of the CSF Aβ pattern after incubation with a 0%, b 0.05%, c 0.5% and d 5% human blood. The inset shows the
degradation of Aβ1-16, and the vertical dashed line indicates its monoisotopic m/z. * represents an unidentified peak, of three Da higher mass than
the monoisotopic peak of Aβ1-16. The Arg13C15N will appear as a mass shift of 10 Da relative the endogenous peptide as seen for Aβ1-19 and Aβ1-20
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labeled Aβ1-40 Arg13C15N, with different percentages of
fresh blood (v/v). The addition of blood produced an Aβ
peptide pattern similar to that of patients with acute
phase bacterial meningitis, with increased levels of Aβ1-
19 and Aβ1-20 (Fig. 2). Degradation of Aβ1-40 was veri-
fied by the detection of Aβ1-19 Arg13C15N and Aβ1-20
Arg13C15N from the added stable isotope labeled Aβ1-40
Arg13C15N (Fig. 2c-d). Other proteolytic activity de-
graded endogenous Aβ1-16 further, as is evident by the
decreasing abundance of the peptide signal (Fig. 2, inset).
In the sample incubated with 0.5% blood in the CSF
(Fig. 2d), endogenous Aβ1-16 was undetectable.
These proteolytic activities were not dependent on
CSF-specific factors, since a similar degradation pattern
was observed when replacing CSF with PBS buffer in the
experiment above, resulting in proteolysis of the stable
isotope labeled Aβ1-40 into similar shorter peptides as
observed in CSF (Fig. 3).
The Aβ degrading activity is present in blood
components
To pinpoint the origin of the observed proteolytic activ-
ity, blood was fractionated into leukocytes, thrombo-
cytes, thrombocyte-free plasma, and erythrocytes. The
fractions were spiked with Aβ1-40, incubated as
described above, and analyzed by IP-MALDI MS (Fig. 4).
While minor degradation was observed in the thrombo-
cyte fraction, the major effect was observed in the
leukocyte and erythrocyte fractions where Aβ1-40 was
clearly degraded into shorter Aβ peptides, preferentially
Aβ1-20. Further experiments showed some Aβ1-40
degradation after incubation with 5% serum but
almost no degradation in the presence of plasma
(Additional file 2 Figure S2).
IDE is a candidate protease for CSF Aβ degradation in
acute bacterial meningitis patients
It is known that the protease insulin-degrading enzyme
(IDE) cleaves Aβ between residues 19–20 and 20–21
[34]. To test if the observed Aβ degradation was caused
by IDE, stable isotope labeled Aβ1-40 Arg13C15N and
IDE were added to CSF from healthy individuals,
followed by incubation and subsequent IP-MALDI MS
analysis. Massive degradation of Aβ was observed, the
most prominent cleavage products being Aβ1-19, Aβ1-
20 and Aβ1-28 (Fig. 5a, b).
To investigate if the IDE-mediated proteolytic activity
could be inhibited, we added increasing amounts of in-
sulin to aliquots of PBS spiked with Aβ1-40 Arg13C15N.
As hypothesized, the abundance of Aβ1-20 decreased
with increasing insulin concentration, while Aβ1-40
increased (Fig. 5c).
An anti-Aβ antibody blocks degradation of Aβ in serum
It has previously been shown that anti-amyloid treat-
ment using some Aβ-specific monoclonal antibodies,
such as the mid-domain anti-Aβ antibody solanezumab
[14, 45] and the C-terminal (Aβ X-40) antibody ponezu-
mab [9, 22] increases plasma Aβ concentration up to
thousand-fold compared to physiological levels (For re-
view, see [7]). It has been suggested that this increase
may be caused by some antibodies blocking the cleavage
sites of proteases that normally degrade Aβ [7]. To
explore this hypothesis, we tested the effect of recom-
binant versions of the antibodies solanezumab [14],
bapineuzumab [47], and crenezumab [53]. The anti-Aβ
antibodies were incubated together with Aβ1-40 in the
presence of 5% serum (Fig. 6). While incubation in 5%
serum in the absence of antibody gave rise to multiple
shorter Aβ peptides including Aβ1-19 and Aβ1-20
(Fig. 6b), the proteolytic degradation was effectively
abrogated when the sample was pre-treated with recom-
binant solanezumab antibody (Fig. 6c). In contrast, incu-
bation in the presence of recombinant crenezumab
(Fig. 6d) and bapineuzumab (Fig. 6e) antibodies did not
block the degradation of Aβ.
A
B
Fig. 3 Mass spectra of PBS spiked with Aβ1-40 Arg13C15N, incubated
overnight in the absence (a) and presence (b) of 0.5% blood. In b,
Several Aβ degradation products are detected as well as a cluster of
signature peaks from blood in the mass range 3300 – 3600 Da, the
identities of which are unknown
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Discussion
We report on an enzymatic 18O labeling-mass spec-
trometry assay for determination of the relative
amount of the peptides formed by endogenous pro-
teolytic activity. 18O-labeling has previously been used
for determination of proteins’ C-termini [41], for the
identification of cross-linked peptides in proteolytic
peptide mixtures [1], to assist the interpretation of
fragment ion mass spectra [43], for generating cali-
brators for mass spectrometric protein quantification
[31], and for differential analysis of protein mixtures
[2, 30, 52, 55]. In a recent paper, 18O-labeling was
used to monitor proteolytic degradation during
sample preparation of mouse brain [48]. Here we
show for the first time that 18O-labeling can also be
used to detect endogenous proteolytic activity associ-
ated with disease. While the current study focuses on
the processing of Aβ, the method may be applied to
detect proteolytic processing events leading to the
formation of any peptide and could thus be a univer-
sal tool to assess the integrity of CSF peptides over
time; an important aspect in the development of
biomarkers.
In bacterial meningitis, activated neutrophils are acti-
vated and released. Using 18O-labeling, we found that
proteolytic activity in the CSF from patients with
Fig. 4 Mass spectra of Aβ1-40 proteolytic products after incubation with a leukocytes, b thrombocytes, c plasma without thrombocytes, and
d erythrocytes
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bacterial meningitis in the acute phase degrades full-
length Aβ peptides into shorter forms, with Aβ1-19, Aβ1-
20 and Aβ1-24 being prominent cleavage products. In
CSF samples from bacterial meningitis patients taken after
antibiotic treatment, the activity was abrogated, also con-
curring previous data showing that Aβ1-42 in CSF is nor-
mally stable over time, even at room temperature [4].
Spiking CSF and solutions containing Aβ with blood
produced the similar Aβ fragments as in CSF from pa-
tients with bacterial meningitis, suggesting a blood com-
ponent as the likely source of the observed activity.
Similar activity was observed when Aβ1-40 was incu-
bated with serum. The lesser activity observed in plasma
likely reflects the presence of EDTA in the collection
tubes, which previously has been shown to inhibit IDE
proteolytic activity [25]. Further spiking experiments
showed that the proteolytic activity resided in leukocytes
as well as erythrocytes. IDE activity has previously been
associated with leukocytes [42] and erythrocytes [44].
In-vitro experiments have shown that IDE can cleave Aβ
between position 19 and 20, and 20 and 21 in the amino
acid sequence [29], suggesting it as a possible mediator
of the observed activity. We also detected prominent
Aβ1-19 and Aβ1-20 signals in CSF samples spiked with
IDE (Fig. 5). There are some differences between the re-
sults obtained with PBS spiked with blood. For example,
a prominent Aβ1-28 signal is present in CSF incubated
with IDE but absent in Aβ1-40 incubated with blood.
This may be attributed to other proteolytic activities in
blood that further degrade Aβ1-28 to shorter Aβ species.
Similarly, Aβ1-24 in an Aβ1-40 sample spiked with
blood may be the product of other blood-derived
proteases.
IDE is a zinc-metallopeptidase which has been impli-
cated in several prevalent diseases including Type 2
diabetes mellitus and AD [12]. IDE has been found to
degrade and influence brain Aβ in experimental animal
models [3, 23, 32, 54] and it has also been shown to be
present in serum [25] and CSF [40]. In the present
experiments, no formation of Aβ1-19 or Aβ1-20 was
observed in CSF samples from patients taken after anti-
biotics treatment with normalized leukocyte counts.
Furthermore, it has previously been shown that Aβ1-42
in CSF is normally stable over time, even at room
temperature [4].
Our results indicate that cleavages at positions Aβ19
and Aβ20 represents a significant pathway for physio-
logical Aβ degradation in blood, and that these cleavages
may be mediated by IDE. Since IDE-deficient mice show
accumulation of Aβ protein [15], hyperinsulinemia and
glucose intolerance enhancing or emulating the activity
of IDE may lower the Aβ burden and may be of interest
to pursue as an AD-treatment.
The dramatic increase observed in plasma Aβ, in re-
sponse to treatment with Aβ-specific monoclonal anti-
bodies [14, 45] has been attributed to increased
clearance of soluble Aβ from the brain into the periph-
ery. According to the peripheral sink hypothesis, the
therapeutic antibody changes the equilibrium for Aβ
between the brain and plasma, with increased clearance
from the brain and a resulting increase in plasma Aβ
levels [11]. However, studies in mouse models, in which
the peripheral level of Aβ was decreased by either by re-
ducing production or increasing degradation of Aβ in
the periphery, failed to show any effect on Aβ levels in
the brain [16, 20, 51]. An alternative hypothesis is that
some anti-Aβ antibodies cause a prolonged half-life of
Aβ peptides in the bloodstream by blocking protease
cleavage sites [7].
Here we show that treatment with a recombinant ver-
sion of solanezumab protects Aβ from degradation in
serum. In contrast, bapineuzumab or crenezumab did
not affect the Aβ peptide profiles, with the exception
that Aβ1-13 seems to increase. This difference may be
due to the much lower affinity of crenezumab [10] and
A
C
B
Fig. 5 Mass spectra of CSF spiked with Aβ1-40 and its proteolytic
products, after incubation with a IDE, and b IDE and insulin. c Scatter
plot of Aβ1-20 and Aβ1-40 versus log insulin conc. in PBS spiked
with Aβ1-40 and IDE after incubation with insulin at
different concentrations
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bapineuzumab than solanezumab for Aβ. The patho-
physiological relevance of the observations needs to be
determined in future studies.
Conclusions
In the present study, we show that a technique based
on enzymatic 18O labeling-mass spectrometry is useful
for identifying and determining the relative amount of
peptides formed by endogenous proteolytic activity in
human CSF. Using this technique we found an en-
zymatic activity in blood leukocytes and erythrocytes
that was identified as IDE that cleaves Aβ in the mid-
domain of the peptide, and could be inhibited by a
recombinant version of the mid-domain anti-Aβ anti-
body solanezumab. If, as these results suggest, the in-
crease in plasma Aβ upon treatment with some Aβ-
specific antibodies is caused by blocking the protease
cleavage site, that is that the higher affinity antibody
(solanezumab) reduces IDE processing of the peptide,
it should be considered that therapeutic antibodies
may in fact interfere with Aβ clearance by stabilizing
Aβ peptides.
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